Personalized Medicine – Products

InSphero, takes a leading role in the recently awarded Chips JU European UNLOOC Project to advance its technology platform and address diversity in drug efficacy and safety testing.

Oxford Nanopore, announced a landmark strategic partnership with the UK Government. This partnership brings together the UK’s world-class scientific organisations Genomics England, UK Biobank and NHS England, alongside Oxford Nanopore.

Thermo Fisher Scientific has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients eligible for treatment with Servier Pharmaceuticals.

iPSC-derived organoid technology drives advances in drug discovery, disease modeling, and personalized medicine. Our cardiac, brain, intestinal, and liver organoids are essential for disease research and therapeutic development.

MOBILion Systems, Inc., announced a next-generation approach for complex sample analysis poised to disrupt the mass spectrometry industry as it delivers unparalleled speed, sensitivity, specificity and quantitative accuracy.

Azenta, Inc. has announced its participation in the FinnGen project, a large-scale research initiative at the forefront of personalized medicine in Finland.

New protein sequencing ‘proof-of-concept' method published in Nature shows promise in sequencing long, intact protein strands at single molecule resolution.

Archer CGP research assays now enable homologous recombination deficiency (HRD) assessment for identification of key biomarkers critical for cancer research.

DNAnexus, Inc., provider of the Precision Health Data Cloud, and Galatea Bio, committed to 'Precision Health at Scale for All,' announced a strategic collaboration to enhance biomedical research and precision medicine.

Scale Biosciences (Scale Bio), announced the launch of the “100 Million Cell Challenge,” a global initiative aimed at pushing the boundaries of single-cell genomics research.